Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer
Toggle Summary Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society
SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference
Toggle Summary Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
- Significant continued improvements in neuromuscular and respiratory function observed in all treated patients, with follow-up assessments ranging from 4 to 48 weeks - Three patients have achieved complete ventilator independence - Encouraging initial safety and efficacy results observed in Cohort
Toggle Summary Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate
Toggle Summary Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
- Oral presentation to include new data from ASPIRO out to 48-weeks of follow-up in the earliest treated patients in dose Cohort 1, and preliminary safety and efficacy data from the sentinel patient in dose Cohort 2 - Oral presentation to be held during a session on new therapeutic modalities
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Aug. 29, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in
Toggle Summary Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
- Designation granted based on positive interim data from ASPIRO clinical trial - RMAT designation enables closer and more frequent multidisciplinary interaction with FDA and includes all of the benefits of breakthrough therapy designation - Plan to meet with FDA to gain alignment on AT132
Toggle Summary Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO , Aug. 9, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles ,
Toggle Summary Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
-          Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western blot, and significant improvement in histology in first three treated patients at 24-week timepoint -          Efficacy